Tonsillar Ectopia

Determining if a Relationship Exists Between Tonsillar Ectopia and Symptom Presentation in Chiari Malformation Patients

Author: Julia R. Saling, B.S.1, Paige Marty, B.S.2, Rebecca Fischbein, Ph.D3, Michelle Chyatte, Dr.PH., MPH4

Author Affiliations:

1 Student Research Fellow, Northeast Ohio Medical University

2 Student Research Fellow, Northeast Ohio Medical University

Research Coordinator and Assistant Professor of Family and Community Medicine, Northeast Ohio Medical University

4 Assistant Professor of Family and Community Medicine, Northeast Ohio Medical University

[button link=”http://msrj.chm.msu.edu/wp-content/uploads/2016/08/TonsillarEctopiaepub.pdf” type=”big” color=”green” newwindow=”yes”] Full Text Article PDF[/button]

Corresponding Author: Julia R. Saling, jsaling@neomed.edu

Key Words: Chiari Malformation Type I, Tonsillar Ectopia, Symptom Presentation

 

Abstract:

Purpose

Chiari Malformation Type I (CM I) is characterized by cerebellar tonsil ectopia and has varying symptomatology . Previous research has shown a relationship between tonsillar dominance and related conditions but few examined association with symptomatology. This study attempts to elucidate a relationship between cerebellar tonsil dominance, age, and symptomatology.

Methods

Data from CM I patients were extracted from the Conquer Chiari Patient Registry. Tonsillar dominance was determined using a ratio of right-to-left herniation length. Pearson’s correlation and one-tailed Student’s T-test were used for analysis.

Results

Length of tonsillar descent appears to be negatively correlated to age of onset (r = -0.266; p < 0.001; n = 113) and diagnosis (r = -0.323; p < 0.001; n = 113). No correlation was found between tonsillar dominance and symptom location, nor between tonsillar dominance and symptom severity bilaterally (p > 0.05).  Symptom location and severity ratios appear to be correlated (r = 0.666; p < 0.001). Tonsillar descent length appears to be strongly correlated bilaterally (r = 0.972; p < 0.001; n = 50).

Conclusion
Inconsistency between tonsillar dominance as related to symptomatology suggests a multifactorial contribution to clinical presentation. The inverse relationship between tonsillar herniation length and age of symptom onset and diagnosis suggests herniation length may be an important predictor for clinical outcomes. Further research is needed to elucidate additional contributing factors and tonsillar dominance and symptomatology association.

 

Published on date: August, 2016

 

DOI: 10.15404/msrj/08.2016.0007

Citation: Saling et al. Determining if a Relationship Exists Between Tonsillar Ectopia and Symptom Presentation in Chiari Malformation Patients Medical Student Research Journal (2016). doi:10.15404/msrj/08.2016.0007

References:

  1. Siasios J, Kapsalaki EZ, Fountas KN. Surgical Management of Patients with Chiari I Malformation. Int J Pediatr. 2012;2012:1-10. doi:10.1155/2012/640127.
  2. Heiss J. Epidemiology of the Chiari I Malformation. In: Tubbs RS, Oakes WJ, eds. The Chiari Malformations. New York: Springer Science + Business Media; 2013:83-92.
  3. Milhorat TH, Chou MW, Trinidad EM, et al. Chiari I malformation redefined: Clinical and radiographic findings for 364 symptomatic patients. Neurosurgery. 1999;44(5):1005-1017. doi:10.1097/00006123-199905000-00042.
  4. Deng X, Wang K, Wu L, et al. Asymmetry of tonsillar ectopia, syringomyelia and clinical manifestations in adult Chiari I malformation. Acta Neurochir (Wien). 2014;156(4):715-722. doi:10.1007/s00701-014-2000-5.
  5. Tubbs RS, Wellons JC, Oakes WJ. Asymmetry of tonsillar ectopia in Chiari I malformation. Pediatr Neurosurg. 2002;37(4):199-202. doi:10.1159/000065399.
  6. Wu T, Zhu Z, Sun X, et al. Is curve direction correlated with the side of dominant displacement of cerebellar tonsil and syrinx deviation in thoracic scoliosis secondary to Chiari malformation type I and syringomyelia? Stud Health Technol Inform. 2012;176(Cmi):286-290. doi:10.3233/978-1-61499-067-3-286.
  7. Kaplan Y, Oksuz E. Chronic migraine associated with the Chiari type 1 malformation. Clin Neurol Neurosurg. 2008;110(8):818-822. doi:10.1016/j.clineuro.2008.05.016.
  8. Lewis AR, Kline LB, Sharpe JA. Acquired esotropia due to Arnold-Chiari I malformation. J Neuro-Ophthalmology. 1996;16(1):49-54. <Go to ISI>://WOS:A1996UE52700012.
  9. Shamji MF, Ventureyra ECG, Baronia B, Nzau M, Vassilyadi M. Classification of symptomatic Chiari I malformation to guide surgical strategy. Can J Neurol Sci. 2010;37(4):482-487. doi:10.1017/S0317167100010507.
  10. Brandon W. Smith, M.D., M.S.C.R.1, Jennifer Strahle, M.D.1, J. Rajiv Bapuraj, M.D.2, Karin M. Muraszko, M.D.1, Hugh J. L. Garton, M.D., M.H.Sc.1, and Cormac O. Maher MD. Distribution of cerebellar tonsil position: implications for understanding Chiari malformation Clinical article. J Nerosurgery. 2013;119(3):812-819.
  11. Christophe C, Bernard D. Magnetic resonance imaging cranial and cerebral dimensions: Is there a relationship with Chiari I malformation? A preliminary report in children. Eur J Paediatr Neurol. 1999;3(1):15-24. doi:10.1053/ejpn.1999.0174.
  12. Fischbein R, Saling JR, Marty P, et al. Patient-reported Chiari malformation type I symptoms and diagnostic experiences: a report from the national Conquer Chiari Patient Registry database. Neurological Sciences. 2015.
  13. Meeker J, Amerine J, Kropp D, Chyatte M, Fischbein R. The impact of Chiari malformation on daily activities: A report from the national Conquer Chiari Patient Registry database. Disabil Health J. 2015;8(4):521-526. doi:10.1016/j.dhjo.2015.01.003.
  14. Aitken LA, Lindan CE, Sidney S, Gupta N, Barkovich AJ, SorelM et al (2009) Chiari type I malformation in a pediatric population. Pediatr Neurol 40(6):449–454
  15.  Speer MC, Enterline DS, Mehltretter L, Hammock P, Joseph J,Dickerson M et al (2014) Chiari type I malformation with or without syringomyelia: prevalence and genetics. J Genet Couns12(4):297–311

Wallis Implant

Pain Relief and Intervertebral Disc Rehydration Following Wallis® Interspinous Device Implantation: a Case Report.

Author: Carter R. Mohnssen, B.S.1,2, Kenneth Pettine, MD2, and Nicole Rittenhouse, MA, CCRC2

Author Affiliations:

1 Creighton University School of Medicine, Omaha, Nebraska, USA.

2 The Spine Institute, Loveland, Colorado, USA.

[button link=”http://msrj.chm.msu.edu/wp-content/uploads/2016/08/WallisImplantepub.pdf” type=”big” color=”green” newwindow=”yes”] Full Text Article PDF[/button]

Corresponding Author: Carter Mohnssen, CarterMohnssen@creighton.edu

Key Words: intervertebral disc degeneration, case reports, orthopedics, therapeutics, biologics

 

Abstract:

Introduction: Degeneration of the lumbar motion segment is the primary cause of low back pain in many individuals. Therefore, new minimally invasive treatments are being sought.

Patient Profile: A 47-year old man presented with severe low back pain and radicular symptoms of several years duration. Lumbar MRI revealed severe desiccation, loss of disc height, and an annular tear with right lateral disc protrusion at L4-5.

Interventions/Outcomes: After conservative treatment failed, the patient received a Wallis® interspinous spacer at the affected level. 100% subjective pain relief was obtained at 3 months post-op. Nucleus pulposus rehydration on MRI was observed.

Discussion: Controversy exists over whether disc dehydration is a reliable indicator of low back pain; however, interspinous spacers seem to alter abnormal motion segment’s biomechanics in a way that results in alleviation of low back pain and increased range of motion. With the advent of biologic therapy, this may provide an intriguing minimally invasive treatment modality, although further research is needed.

 

Published on date: August, 2016

 

DOI: 10.15404/msrj/04.2016.0006

Citation: Mohnssen, C. Pain relief and intervertebral disc rehydration following Wallis interspinous device implantation: a case report. Medical Student Research Journal (2016). doi: 10.15404/msrj/04.2016.0006

References:

  1. Luoma K, Riihimaki H, Luukkonen R, Raininko R, Viikari-Juntura E, Lamminem A. Low back pain in relation to lumbar disc degeneration. Spine. February 2000; 25:487-92.
  2. Mooney V, Robertson J. The facet syndrome. Clinical Orthopedic Related Research. March-April 1976; 115:149-56.
  3. Kirkaldy-Willis WH, Wedge JH, Yong-Hing K, Reilly J. Pathology and pathogenesis of lumbar spondylosis and stenosis. Spine. December 1978; 3:319-27.
  4. Yang KH, King AI. Mechanism of facet load transmission as a hypothesis for low-back pain. Spine. September 1984; 9:557-65.
  5. Guyer RD, McAfee PC, Banco RJ, et al. Prospective, randomized, multicenter Food and Drug Administration investigational device exemption study of total artificial disc replacement with the CHARITE artificial disc versus lumbar fusion: five year follow-up. Spine. May 2009; 9(5): 374-86.
  6. Zigler J, Delamarter R, Spivak JM, et al. Results of the prospective, randomized, multicenter Food and Drug Administration investigational device exemption study of the ProDisc-L total disc replacement versus circumferential fusion for the treatment of 1-level degenerative disc disease. Spine. May 2007; 15;32(11): 1155-62.
  7. Sénégas J. Minimally invasive dynamic stabilisation of the lumbar motion segment with an interspinous implant. Minimally Invasive Spine Surgery: A Manual, edited by HM Mayer. 2005; 459-65.
  8. Sénégas J. Mechanical supplementation by non-rigid fixation in degenerative intervertebral lumbar segments: the Wallis system. European Spine Journal. October 2002; Suppl 2 S164-69.
  9. Sénégas J, Vital JM, Pointillart V, Mangione P. Clinical evaluation of a lumbar interpsinous dynamic stabilization device (the Wallis system) with a 13-year mean follow up. Neurosurgery Review. July 2009; 32:335-342.
  10. Boeree NR. Dynamic stabilization of the degenerative lumbar motion segment: the Wallis system. Spinal Arthroplasty Society Annual Meeting. May 2005; New York, New York.
  11. Sandu N, Schaller B, Arasho B, Orabi M. Wallis implantation to treat degenerative spine disease: description of the method and case series. Expert Review of  Neurotherapeutics. June 2011; 11(6):799-807.
  12. Gazzeri R, Galarza M, Alfieri A. Controversies about Interspinous Process Devices in the Treatment of Degenerative Lumbar Spine Diseases: Past, Present, and Future. Biomed Research International. Volume 2014 (2014); 15 pages.
  13. Lotz JC, Chin JR. Intervertebral disc cell death is dependent on the magnitude and duration of spinal loading. Spine. June 2000; 25:1477–1483.
  14. Zeiter S, Bishop NE, Ito K. Significance of the mechanical environment during regeneration of the intervertebral disc. European Spine Journal. November 2005; 14:874-79.
  15. Minns RJ, Walsh WK. Preliminary design and experimental studies of a novel soft implant for correcting sagittal plane instability in the lumbar spine. Spine. August 1997; 22(16):1819-25.
  16. Zucherman JF, Hsu KY, Hartjen CA, Mehalic TF, et al. A Multicenter, Prospective, Randomized Trial Evaluating the X STOP Interspinous Process Decompression System for the Treatment of Neurogenic Intermittent Claudication: Two-Year Follow-Up Results. Spine. June 2005; 30(12):1351-1358.
  17. DePalma M. Biologic Treatments for Discogenic Low Back Pain. SpineLine. April 2012; 19-26.
  18. Hohaus C, Ganey T, Minkus Y, Meisel H. Cell transplantation in lumbar spine disc degeneration disease. European Spine Journal. November 2008; 17(Suppl 4):S492-S503.